Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis
Authors:
- Roberto FurlanRFRoberto Furlan
- Sabine SchaedelinSSSabine Schaedelin
- Jette Lautrup FrederiksenJFJette Lautrup Frederiksen
- Mitsuru WatanabeMWMitsuru Watanabe
- Noriko IsobeNINoriko Isobe
- Fredrik PiehlFPFredrik Piehl
- Katharina FinkKFKatharina Fink
- Ellen IacobaeusEIEllen Iacobaeus
- Björn EvertssonBEBjörn Evertsson
- Mohsen KhademiMKMohsen Khademi
- Matteo GastaldiMGMatteo Gastaldi
- Giacomo GrecoGGGiacomo Greco
Open Access
- 24 September 2025
- journal article
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (4) , 1319-1331
Abstract
Granulocytes play a well-established role in the pathogenesis of brain tissue damage in neuromyelitis optica spectrum disorder (NMOSD). The release of granulocyte activation markers (GAM) into CSF has recently been shown to distinguish NMOSD from multiple sclerosis (MS) with high accuracy. However, their pathogenetic role in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is less clear, and their usefulness for diagnostic differentiation is unknown. This observational cohort study by eight tertiary centres in Europe and Japan included 244 CSF samples from patients with MOGAD (n = 71), NMOSD (n = 48), MS (n = 125) and control persons (n = 19). CSF levels of GAM [neutrophil elastase, myeloperoxidase, neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-8 and 9 (MMP-8, MMP-9)], astrocyte damage markers [ADM: glial fibrillary acidic protein (GFAP), S100B], and complement factors C5 and C5a were analysed by capillary ELISA (Ella™) or Luminex®. The primary outcome was the capacity of these markers to differentiate MOGAD, NMOSD and MS in the acute (≤21 days post-exacerbation) stage, and the correlation of GAM with C5 and C5a. Secondary analyses included the correlations of these markers with disability severity, measured by the Expanded Disability Status Scale (EDSS). GAM (except for MMP-9), ADM and C5/C5a levels peaked at onset of disease exacerbation of MOGAD and NMOSD (regardless of aquaporin-4 antibody status), and were significantly higher than in MS. MMP-9 levels were continuously increased in MS over MOGAD and NMOSD, both in acute and subacute/chronic stages. C5 and C5a were equally increased over MS in acute stages of MOGAD and NMOSD. A logistic model and receiver operating characteristics analyses incorporating GAM and C5 displayed high discriminatory power between MOGAD/NMOSD versus MS [area under the curve (AUC) = 0.880], NMOSD versus MS (AUC = 0.837) and MOGAD versus MS (AUC = 0.925) in acute stages. Accordingly, increased ADM levels in NMOSD differentiated NMOSD from MS and MOGAD (AUC = 0.897 and 0.843, respectively). GAM levels correlated with EDSS scores in MOGAD and NMOSD, but not in MS, while those of ADM correlated with disability in NMOSD, but not in MOGAD and MS. Determining CSF levels of GAM and C5/C5a, and of ADM provide a biology-driven approach to differentiate MOGAD, NMOSD and MS. Their measurement can be processed faster and with similar accuracy than with most autoantibody assays, enabling timely initiation of appropriate therapy in acute presentations. The correlation between GAM and C5/C5a levels with neurological impairment in MOGAD and NMOSD corroborates their role as effectors of neural damage, supporting the acute stage use of inhibitors of C5 activation.Keywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030_189140/1)
- Health and Labour Sciences Research
- Ministrstvo za zdravje
- Labour and Welfare of Japan
- Medicinska Forskningsrådet (2020–02700)
This publication has 50 references indexed in Scilit:
- Real‐world clinical experience with serum MOG and AQP4 antibody testing by live versus fixed cell‐based assayAnnals of Clinical and Translational Neurology, 2025
- Update on aquaporin-4 antibody detection: the early diagnosis of neuromyelitis optica spectrum disordersMultiple Sclerosis and Related Disorders, 2024
- Diagnostic Utility of MOG Antibody Testing in Cerebrospinal FluidAnnals of Neurology, 2024
- Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGADAnnals of Neurology, 2024
- Eculizumab for a catastrophic relapse in NMOSD: case reportNeurological Sciences, 2023
- Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGADNeurotherapeutics, 2022
- The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibodyActa Neuropathologica, 2020
- Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis opticaJournal of Neuroimmunology, 2013
- Neutrophil protease inhibition reduces neuromyelitis optica–immunoglobulin G–induced damage in mouse brainAnnals of Neurology, 2011
- Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanismsAnnals of Neurology, 2011